Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $354,150.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 15,000 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $23.61, for a total transaction of $354,150.00. Following the completion of the sale, the chief executive officer owned 362,152 shares in the company, valued at $8,550,408.72. This represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.84, for a total transaction of $122,441.16.
• On Thursday, March 19th, Claire Mazumdar sold 6,905 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.78, for a total transaction of $129,675.90.
• On Friday, March 20th, Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.95, for a total transaction of $30,244.20.
• On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The stock was sold at an average price of $19.17, for a total transaction of $704,804.22.
• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total transaction of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total transaction of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.74, for a total transaction of $33,469.64.

Bicara Therapeutics Price Performance

NASDAQ BCAX opened at $23.63 on Thursday. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -9.34 and a beta of -1.23. The company’s fifty day moving average is $19.16 and its two-hundred day moving average is $17.72. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $24.25.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.04. As a group, sell-side analysts expect that Bicara Therapeutics Inc. will post -2.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vestal Point Capital LP lifted its holdings in shares of Bicara Therapeutics by 2.0% during the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after acquiring an additional 100,000 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after purchasing an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC bought a new position in Bicara Therapeutics during the 4th quarter valued at about $44,484,000. Vanguard Group Inc. lifted its holdings in Bicara Therapeutics by 9.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock valued at $34,753,000 after purchasing an additional 195,667 shares during the last quarter. Finally, State Street Corp lifted its holdings in Bicara Therapeutics by 179.5% during the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after purchasing an additional 1,059,260 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BCAX shares. The Goldman Sachs Group raised their price objective on shares of Bicara Therapeutics from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Bank of America started coverage on shares of Bicara Therapeutics in a report on Wednesday, March 25th. They set a “buy” rating and a $35.00 price objective for the company. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. HC Wainwright raised their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Finally, Citigroup started coverage on shares of Bicara Therapeutics in a report on Thursday, January 29th. They set an “outperform” rating for the company. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $28.00.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.